What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Over the past 3 months, 7 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell
• AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Benzinga’s Top Ratings Upgrades, Downgrades For October 17, 2023
Upgrades According to Wolfe Research, the prior rating for TC Energy Corp (NYSE:TRP) was changed from Underperform to…
Analyst Ratings for ACADIA Pharmaceuticals
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: Bullish Somewhat Bullish Indifferent…
Benzinga’s Top Ratings Upgrades, Downgrades For October 10, 2023
Upgrades According to RBC Capital, the prior rating for Montrose Environmental Group Inc (NYSE:MEG) was changed from Sector…
Electronic Arts To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Tuesday
JP Morgan increased ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) price target from $29 to $32. JP Morgan analyst Tessa Romero upgraded the stock from Neutral to Overweight. ACADIA Pharmaceuticals shares rose 0.3% to close at $21.74 on Monday.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Bionomics (NASDAQ:BNOX) stock increased by 261.4% to $3.56 during Thursday’s regular session. As of 13:30 EST, Bionomics’s…
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Gainers
Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.